Abstract
We aimed to summarise recent advances in the therapy of diabetic neuropathy. Although all therapeutic choices in the treatment of diabetes mellitus itself are based on clear pathophysiological basis, this approach is less present in the treatment of the “forgotten complication”, diabetic neuropathy. As part of pathogenetic oriented treatment, the role of glycemic control and cardiovascular risk factors are reviewed. The mode of action of benfotiamine is based on inhibition of key alternative pathways, including the polyol, hexosamine, protein-kinase-C pathways, and inhibition of advanced glycation end products formation, just as on activation of transketolase. Alpha- lipoic-acid is considered as the most potent antioxidant. Other forms of pathogenetic oriented treatment, including actovegin, will be summarised. The anticonvulsants gabapentin and pregabalin, as well as the antidepressant duloxetine represent the most important new drugs among agents for symptomatic relief. Most likely, we should offer combination treatment to our patients much more often, first of all combination of pathogenetic and symptomatic drugs. Finally, the broad spectrum of non-pharmacological treatment will be reviewed.
Keywords: Diabetic neuropathy, benfotiamine, alpha-lipoic-acid, gabapentin, pregabalin, duloxetine.
Current Pharmaceutical Design
Title:Current Options and Perspectives in the Treatment of Diabetic Neuropathy
Volume: 19 Issue: 27
Author(s): Tamas Varkonyi, Zsuzsanna Putz, Katalin Keresztes, Timea Martos, Csaba Lengyel, Alin Stirban, Gyorgy Jermendy and Peter Kempler
Affiliation:
Keywords: Diabetic neuropathy, benfotiamine, alpha-lipoic-acid, gabapentin, pregabalin, duloxetine.
Abstract: We aimed to summarise recent advances in the therapy of diabetic neuropathy. Although all therapeutic choices in the treatment of diabetes mellitus itself are based on clear pathophysiological basis, this approach is less present in the treatment of the “forgotten complication”, diabetic neuropathy. As part of pathogenetic oriented treatment, the role of glycemic control and cardiovascular risk factors are reviewed. The mode of action of benfotiamine is based on inhibition of key alternative pathways, including the polyol, hexosamine, protein-kinase-C pathways, and inhibition of advanced glycation end products formation, just as on activation of transketolase. Alpha- lipoic-acid is considered as the most potent antioxidant. Other forms of pathogenetic oriented treatment, including actovegin, will be summarised. The anticonvulsants gabapentin and pregabalin, as well as the antidepressant duloxetine represent the most important new drugs among agents for symptomatic relief. Most likely, we should offer combination treatment to our patients much more often, first of all combination of pathogenetic and symptomatic drugs. Finally, the broad spectrum of non-pharmacological treatment will be reviewed.
Export Options
About this article
Cite this article as:
Varkonyi Tamas, Putz Zsuzsanna, Keresztes Katalin, Martos Timea, Lengyel Csaba, Stirban Alin, Jermendy Gyorgy and Kempler Peter, Current Options and Perspectives in the Treatment of Diabetic Neuropathy, Current Pharmaceutical Design 2013; 19 (27) . https://dx.doi.org/10.2174/13816128113199990310
DOI https://dx.doi.org/10.2174/13816128113199990310 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Palmitoylethanolamide Relieves Pain and Preserves Pancreatic Islet Cells in a Murine Model of Diabetes
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic: Pain - Unmet Need and Emerging Targets & Therapies (Guest Editor: Sivaram Pillarisetti)]
CNS & Neurological Disorders - Drug Targets Amyloidogenesis of Natively Unfolded Proteins
Current Alzheimer Research Microdialysis as an Excellent Sampling Approach for Biomedical Analysis
Current Pharmaceutical Analysis SiRNA Nanotherapeutics _The Panacea of Diseases?
Current Gene Therapy Amyloidosis and Auto-Inflammatory Syndromes
Current Drug Targets - Inflammation & Allergy Hypocholesterolemia
Current Vascular Pharmacology Hyperglycemia-induced Oxidative Stress and its Role in Diabetes Mellitus Related Cardiovascular Diseases
Current Pharmaceutical Design The Saphenous Vein as a Bypass Conduit: The Potential Role of Vascular Nerves in Graft Performance
Current Vascular Pharmacology Subject Index to Volume 10
Current Medicinal Chemistry Restless Legs Syndrome After Single Low Dose Quetiapine Administration
Current Drug Safety Role of Advanced Glycation End Products in Diabetic Neuropathy
Current Pharmaceutical Design Baroreflex Function: Determinants in Healthy Subjects and Disturbances in Diabetes, Obesity and Metabolic Syndrome
Current Diabetes Reviews African Plants with Antidiabetic Potentials: Beyond Glycaemic Control to Central Nervous System Benefits
Current Diabetes Reviews The Impact of Bariatric Surgery in Patients with Type-2 Diabetes Mellitus
Current Diabetes Reviews UGT1A1 Mediated Drug Interactions and its Clinical Relevance
Current Drug Metabolism Chalcone Derivatives Activate and Desensitize the Transient Receptor Potential Ankyrin 1 Cation Channel, Subfamily A, Member 1 TRPA1 Ion Channel: Structure-Activity Relationships in vitro and Anti-Nociceptive and Anti-inflammatory Activity in vivo
CNS & Neurological Disorders - Drug Targets Synthesis and Biological Interest of Structured Docosahexaenoic Acid–Containing Triacylglycerols and Phospholipids
Current Organic Chemistry Neuroprotective Effects of Exercise Treatments After Injury: The Dual Role of Neurotrophic Factors
Current Neuropharmacology Antiretroviral Drugs and The Kidney: Dosage Adjustment and Renal Tolerance
Current Pharmaceutical Design